Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 8/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bolasterone SCHEMBL10904938 | 1.00 | SHBG (1.00) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| Bolasterone SCHEMBL5656551 | 1.00 | SHBG (1.00) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| Calusterone SCHEMBL4509 | 1.00 | SHBG (1.00) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| Bolasterone SCHEMBL11876760 | 1.00 | SHBG (1.00) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| Bolasterone SCHEMBL4945157 | 1.00 | SHBG (1.00) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| SCHEMBL8340651 | 0.90 | SHBG (0.82) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| SCHEMBL8340653 | 0.90 | SHBG (0.82) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| Calusterone SCHEMBL5323303 | 0.87 | SHBG (0.76) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| SCHEMBL5700143 | 0.86 | SHBG (0.76) | SHBGALDH1A1CYP19A1NR3C1PGR | |
| SCHEMBL5700149 | 0.86 | SHBG (0.76) | SHBGALDH1A1CYP19A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| US-10940151-B2 | Methods for treating renal disease | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-03-09 | — | — | US | claimed |
| EP-3612223-A1 | Treating Male Senescence | National Institute Of Biological Sciences, Beijing (CN) | 2020-02-26 | — | — | EP | claimed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | claimed |
| US-20190117659-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2019-04-25 | — | — | US | claimed |
| US-10130632-B2 | Methods for treating renal disease | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2018-11-20 | — | — | US | claimed |
| WO-2018192416-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-25 | — | — | WO | claimed |
| EP-2470647-B1 | GENETICALLY MODIFIED ORGANISMS FOR THE PRODUCTION OF LIPIDS | NOVOZYMES AS (DK) | 2017-04-19 | — | — | EP | claimed |
| US-9616072-B2 | Reduction of side effects from aromatase inhibitors used for treating breast cancer | CHAVAH PTY LTD. (AU) | 2017-04-11 | — | — | US | claimed |
| US-6011023-A | Angiostatic steroids | ALCON LABORATORIES, INC. (US) | 2000-01-04 | — | — | US | claimed |
| WO-1998034621-A1 | COMPOSITION AND METHOD FOR SUPPLEMENTING TESTOSTERONE IN WOMEN WITH SYMPTOMS OF TESTOSTERONE DEFICIENCY | THERATECH, INC. (US) | 1998-08-13 | — | — | WO | claimed |
| US-5792330-A | Lanthanide metal cations for concurrent detection and separation in capillary electrophoresis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-08-11 | — | — | US | claimed |
| WO-1996038724-A1 | LANTHANIDE METAL CATIONS FOR CONCURRENT DETECTION AND SEPARATION IN CAPILLARY ELECTROPHORESIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-12-05 | — | — | WO | claimed |
| EP-0614463-A1 | ANGIOSTATIC STEROIDS | ALCON LABORATORIES, INC. (US) | 1994-09-14 | — | — | EP | claimed |
| WO-1993010141-A2 | ANGIOSTATIC STEROIDS | ALCON LABORATORIES, INC. (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| EP-0199768-A4 | A METHOD FOR THE PREVENTION OF OCULAR HYPERTENSION, TREATMENT OF GLAUCOMA AND TREATMENT OF OCULAR HYPERTENSION. | KNEPPER PAUL A | 1989-04-26 | — | — | EP | claimed |
| EP-0199768-A1 | A METHOD FOR THE PREVENTION OF OCULAR HYPERTENSION, TREATMENT OF GLAUCOMA AND TREATMENT OF OCULAR HYPERTENSION | KNEPPER, Paul A. (US) | 1986-11-05 | — | — | EP | claimed |
| WO-1986002554-A1 | A METHOD FOR THE PREVENTION OF OCULAR HYPERTENSION, TREATMENT OF GLAUCOMA AND TREATMENT OF OCULAR HYPERTENSION | KNEPPER PAUL A | 1986-05-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117659-A1 | METHODS FOR TREATING RENAL DISEASE | LDLR, APOL1, APOB | SHBG 2277/4885ALDH1A1 4249/4885CYP19A1 4609/4885 |
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | SHBG 293/4885ALDH1A1 2786/4885CYP19A1 669/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | SHBG 293/4885ALDH1A1 2786/4885CYP19A1 669/4885 |
| US-10130632-B2 | Methods for treating renal disease | LDLR, APOL1, APOB | SHBG 2277/4885ALDH1A1 4249/4885CYP19A1 4609/4885 |
| US-10940151-B2 | Methods for treating renal disease | LDLR, APOL1, APOB | SHBG 2277/4885ALDH1A1 4249/4885CYP19A1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.